Beraprost

General information

Beraprost is a stable, orally active analogue of PGI ₂ . It has been tested in patients with intermittent claudication in a randomized, placebo-controlled trial [ ]. Beraprost improved walking distance more often than placebo. It also reduced the incidence of critical cardiovascular events, but the trial was not powered for statistical validation of this effect. As with iloprost, headache and flushing were the most common adverse effects.